Ultragenyx Pharmaceutical | RARE - Pre Tax Profit


Ultragenyx Pharmaceutical reported $-128M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Agios Pharmaceuticals USD -109.06M 5.62M Dec/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
Immunic USD -21.38M 8.2M Jun/2024
Insmed USD -326.93M 41.77M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Karyopharm Therapeutics USD -30.89M 1.16M Dec/2024
Kyowa Hakko Kirin JPY 39.3B 13.35B Dec/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Moderna USD -187M 631M Sep/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025
Xoma USD 15.98M 24.58M Jun/2024